This edition contains the following: First FDA-Approved NASH Drug Expected in 2020: Quick Facts to Know The Tussle Between Resection and Liver Transplantation in the Treatment of HCC “What advice should I give my patients with cirrhosis regarding COVID-19?” Hepatitis B Vaccination: Who Needs It and Which Options are...

This edition contains the following: Living Donor Liver Transplantation An Update on Nonalcoholic Steatohepatitis (NASH) from the International Liver Congress Does direct-acting antiviral exposure affect hepatocellular carcinoma recurrence in patients with HCV cirrhosis? Any News on Hepatitis B Cure?

This edition contains the following: A New First-Line Oral Treatment for Advanced Hepatocellular Carcinoma Comprehensive, Cutting-Edge Care at The Texas Liver Tumor Center An Update on the Management of Severe Thrombocytopenia in Patients With Cirrhosis

This edition contains the following: Autoimmune Hepatitis: Current And Future Treatment Options Cholangiocarcinoma: Diagnosis And Management Is Green Tea Good For Your Health? What Noninvasive Imaging Techniques Can Measure Liver Steatosis? Is Liver Fibrosis Reversible?

This edition contains the following: New Targeted Therapy for HCC Can my patients take over-the-counter herbal and dietary supplements? NAFLD/NASH Update

This edition contains the following: TLI Welcomes Dr. Fabian Rodas Opening of Texas Liver Tumor Center (TLTC) HCC in South Texas Latinos: Is Aflatoxin Exposure Partly to Blame? A Focus on Benign Liver Masses Liver Spot: Pangenotypic HCV Regimens 

This edition contains the following: Dr. Naim Alkhouri, Joins Texas Liver Institute and UT Health Oral Nutrition Supplement for a Patient with Cirrhosis How to Make Low Sodium Diet Appealing to Patients Hepatitis B: Closer to a Complete Cure

This edition contains the following: How Much Alcohol Can I Safely Drink? Does Liver Disease Hurt? Does Replacing Animal Protein With Plant Protein Help People Live Longer? Primary Biliary Cholangitis Living Liver Donation Can Save Lives Otherwise Lost On The Waitlist

This edition contains the following: Frequently Asked Questions on Liver Disease Managing HCV-infected Patients With Decompensated Cirrhosis Nutritional Guidelines for Fat Malabsorption in Cholestatic Liver Disease

This edition contains the following: Grazoprevir and Elbasvir Combination Therapy Portal Vein Thrombosis New Anti-Fibrotic Agent Shows Promise The NASH Pipeline 2016